Interesting news today....
German biotech company Morphosys expects its upcoming rheumatism drug MOR 103 to generate sales of more than $1 billion per year
From July Investor Report and Annual Report...
In-House Activities & Partnerships - Peptide drugs against intractable extracellular targets - In-house anti-CD40L program for Lupus & rheumatoid arthritis
No. of Deal Discussions = 8
Everything ticking along for Phylogica's in-house programs. CD40 ligand program is most advanced. Fully optimized leads ready to go preclinical.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
0.000(0.00%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.44 | $1.34 | $1.022M | 752.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 692 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 5666 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |